Abstract:The main actions of metformin are as follows: To reduce hyperglycemia via the suppression of gluconeogenesis, improve glucose uptake and insulin sensitivity, and stimulate activation of adenosine monophosphate-activated protein kinase during the treatment of diabetes mellitus. It is well known that metformin acts via complex mechanisms, including multitarget and multipathway mechanisms; however, the multi-targeted antidiabetic genes of metformin remain obscure. The present study aimed to perform transcriptomic and proteomic analysis of potential therapeutic target genes in the liver of metformin-treated Sprague-Dawley rats with type 2 diabetes mellitus. The type 2 diabetes rat model was established using streptozotocin. Fasting blood glucose, hemoglobin A1c, serum insulin and biological parameters were subsequently measured. Differentially expressed genes (DEGs) and proteins were identified in the rat livers by expression profile analysis and isobaric tags for relative and absolute quantitation (iTRAQ). A 1.5-fold alteration in gene expression, as determined using chip-based expression profile analysis, and a 1.2-fold alteration in protein expression, as determined using iTRAQ, were considered physiologically significant benchmarks, which were used to identify DEGS in metformin-treated rats with type 2 diabetes mellitus. The DEGs were verified using quantitative polymerase chain reaction (qPCR) and western blot analysis. Numerous hepatic genes involved in various metabolic pathways were affected by metformin; in particular, genes associated with lipid metabolism were markedly affected. Expression profile analysis and iTRAQ analysis suggested that carboxylesterase 1C subunit (Ces1C) and cholesterol 7-hydroxylyase (Cyp7a1) may serve as important DEGs, which were validated by qPCR and western blot analysis. Ces1C and Cyp7a1 are the main enzymes in cholesterol metabolism, yet the result of western blotting was not consistent with qPCR. The present study demonstrated that metformin may affect the expression of numerous hepatic genes involved in metabolic pathways, particularly the lipid and cholesterol metabolic pathways. Ces1C and Cyp7a1 may be considered novel therapeutic target genes in the liver, which are involved in the antidiabetic effects of metformin.

Long Non-Coding RNA and Mrna Profile Analysis of Metformin to Reverse the Pulmonary Hypertension Vascular Remodeling Induced by Monocrotaline.

Long Noncoding RNA Expression Profiles of Hypoxic Pulmonary Hypertension Rat Model.

Transcriptomic and Proteomic Analysis of Potential Therapeutic Target Genes in the Liver of Metformin‑treated Sprague‑Dawley Rats with Type 2 Diabetes Mellitus

Profiling and Molecular Mechanism Analysis of Long Non-Coding RNAs and mRNAs in Pulmonary Arterial Hypertension Rat Models

Protective Role Of Metformin Against Chronic Experimental Pulmonary Arterial Hypertension

Comparative Transcription Profiling of Mrna and Lncrna in Pulmonary Arterial Hypertension after C75 Treatment.

Metformin-Induced Changes of the Coding Transcriptome and Non-Coding RNAs in the Livers of Non-Alcoholic Fatty Liver Disease Mice

Metformin inhibits pulmonary artery smooth muscle cell proliferation by upregulating p21 via NONRATT015587.2

Comparative transcription profiling of mRNA and lncRNA in pulmonary arterial hypertension after C75 treatment

Metformin Improves Pulmonary Artery Remodeling in Chronic Thromboembolic Pulmonary Hypertension Rats

Activation of AMPK Prevents Monocrotaline-Induced Extracellular Matrix Remodeling of Pulmonary Artery.

Down-regulation of lncRNA MALAT1 alleviates vascular lesion and vascular remodeling of rats with hypertension

Expression profile analysis of long non-coding RNAs involved in the metformin-inhibited gluconeogenesis of primary mouse hepatocytes

Differential Expression of Microrna in the Lungs of Rats with Pulmonary Arterial Hypertension

Non-coding RNAs as potential targets in metformin therapy for cancer

Lncrna MALAT1 Participates in Metformin Inhibiting the Proliferation of Breast Cancer Cell

Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline.

Metformin Treatment Modulates Long Non-Coding RNA Isoforms Expression in Human Cells

Integrated Analysis of M6a Mrna Methylation in Rats with Monocrotaline-Induced Pulmonary Arterial Hypertension.

The Role of Mirna-155 in Monocrotaline-Induced Pulmonary Arterial Hypertension Through C-Fos/nlrp3/caspase-1

Metformin suppresses LRG1 and TGFβ1/ALK1-induced angiogenesis and protects against ultrastructural changes in rat diabetic nephropathy